Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sandoz has sued Danish Novo Nordisk in the US District Court, Eastern District of Michigan (Detroit) over a generic version of diabetes drug.
Subscribe to our email newsletter
Sansoz has filed the case with a hope that the court will find that its generic version of Novo Nordisk’s diabetes drug Prandin (repaglinide) is non-infringing, Bloomberg reported.
Sandoz intends to market a generic version of Prandin in low cost.
Prandin (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus).